Three Generations of GLP-1 Drugs, One Pattern

Look at the last decade of metabolic drug development and a clear pattern emerges: each new generation of GLP-1 medication didn't replace the mechanism of the one before it. It added a receptor on top.

Generation one, semaglutide (marketed for weight loss as Wegovy), activates the GLP-1 receptor alone. The mechanism centers on appetite suppression and slowed gastric emptying. Approved in 2017, trial data showed weight loss in the range of roughly 15% at 48 weeks.

Generation two, tirzepatide (Zepbound), activates both GLP-1 and GIP receptors. The addition of GIP brings improved insulin sensitivity into the mechanism alongside appetite effects. Approved in 2023, trial results moved to around 20% weight loss over a similar timeframe.

Generation three, retatrutide, adds a third receptor: glucagon, on top of GLP-1 and GIP. This is the mechanistically interesting addition, because glucagon activation drives energy expenditure directly, rather than only working on the appetite side of the equation. Phase 2 data reported weight loss figures meaningfully higher than the prior two generations at comparable doses; retatrutide remains in Phase 3 development.

The reason this progression matters mechanistically: single-receptor GLP-1 agonism runs into a ceiling, generally cited around the mid-teens percent of body weight lost, because appetite suppression alone triggers metabolic compensation — the body responds to sustained deficit by lowering its resting energy expenditure, partially offsetting the calorie deficit being created. Adding GIP improved the insulin-sensitivity side of the equation. Adding glucagon is what breaks through that compensatory ceiling, because it raises energy expenditure directly rather than relying solely on reduced intake.

That's the throughline worth remembering: this isn't a story about one drug being stronger than another in some vague sense. It's a story about researchers systematically identifying which additional metabolic lever, layered on top of the last, moves the needle on a specific limitation of the previous approach.

Why this matters for tracking: if you're on or considering a GLP-1-class medication, weight change alone is an incomplete picture — how these drugs affect insulin sensitivity, resting energy expenditure, and lean mass varies by which receptors are involved. Tracking relevant bloodwork and body composition, not just the number on the scale, gives you a much clearer read on what's actually happening metabolically.